Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,585,728
  • Shares Outstanding, K 2,604,286
  • Annual Sales, $ 94,943 M
  • Annual Income, $ 17,941 M
  • 60-Month Beta 0.54
  • Price/Sales 4.14
  • Price/Cash Flow 11.61
  • Price/Book 5.14
Trade JNJ with:

Options Overview Details

View History
  • Implied Volatility 20.12% ( +20.12%)
  • Historical Volatility 14.03%
  • IV Percentile 75%
  • IV Rank 54.30%
  • IV High 25.03% on 10/10/22
  • IV Low 14.28% on 12/02/22
  • Put/Call Vol Ratio 1.08
  • Today's Volume 26,853
  • Volume Avg (30-Day) 40,618
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 430,343
  • Open Int (30-Day) 434,865

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate 2.51
  • Number of Estimates 7
  • High Estimate 2.53
  • Low Estimate 2.46
  • Prior Year 2.67
  • Growth Rate Est. (year over year) -5.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.11 +1.69%
on 03/23/23
156.90 -2.71%
on 02/27/23
-3.32 (-2.13%)
since 02/24/23
3-Month
150.11 +1.69%
on 03/23/23
180.93 -15.63%
on 01/06/23
-24.83 (-13.99%)
since 12/23/22
52-Week
150.11 +1.69%
on 03/23/23
186.69 -18.23%
on 04/25/22
-22.59 (-12.89%)
since 03/24/22

Most Recent Stories

More News
3 Popular Large-Cap Stocks to Buy Right Now

As investors continue to digest the news of the recent bank collapses and the Federal Reserve’s quarter-percentage-point rate hike, the stock market outlook seems bumpy for some time. With speculations...

IMGO : 36.01 (+0.03%)
JNJ : 152.65 (+1.01%)
MRK : 104.80 (+0.55%)
V : 221.04 (-0.70%)
3 Large-Cap Pharma Stocks to Protect Your Portfolio Through 2023

The worst banking crisis since 2008 could not stop the Fed from raising the benchmark interest rate. The possibility of further policy tightening and strict lending standards for banks might push the economy...

BMY : 67.68 (+1.05%)
JNJ : 152.65 (+1.01%)
MRK : 104.80 (+0.55%)
4 Best Pharma Stocks to Buy for the Long Haul

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy...

ABMD : 381.02 (+0.06%)
AZN : 67.91 (+0.97%)
BMY : 67.68 (+1.05%)
CINC : 29.06 (-0.48%)
JNJ : 152.65 (+1.01%)
NVS : 83.59 (+1.31%)
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

Smart Beta ETF report for DGRO

DGRO : 48.35 (+0.86%)
JPM : 124.91 (-1.52%)
JNJ : 152.65 (+1.01%)
XOM : 103.53 (+0.12%)
VIG : 149.23 (+0.27%)
EFG : 90.47 (-0.14%)
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

/CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance (NOC) authorizing the...

JNJ : 152.65 (+1.01%)
The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson...

BMY : 67.68 (+1.05%)
JNJ : 152.65 (+1.01%)
NVO : 152.75 (+2.12%)
NVS : 83.59 (+1.31%)
3 Large-Cap Stocks You Can Buy for Under $200

The recent financial turmoil from several bank failures, the Fed’s persistent hawkish stance to battle stubborn inflation, and renewed recession worries have kept the stock market highly volatile lately....

ABMD : 381.02 (+0.06%)
JNJ : 152.65 (+1.01%)
MRK : 104.80 (+0.55%)
TSM : 92.79 (-1.90%)
Have $1,000? 2 Smart Stocks to Buy This Month

The market is still giving investors great opportunities to buy exceptional companies.

JNJ : 152.65 (+1.01%)
MA : 351.63 (-0.77%)
3 Safe Dow Dividend Stocks to Buy Now

These companies combine regimented growth with income for a balanced overall value.

CAT : 217.01 (-1.11%)
HD : 283.02 (-0.31%)
JNJ : 152.65 (+1.01%)
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

Smart Beta ETF report for VYM

VYM : 101.70 (+0.87%)
JPM : 124.91 (-1.52%)
JNJ : 152.65 (+1.01%)
XOM : 103.53 (+0.12%)
VTV : 133.27 (+0.86%)
IWD : 146.38 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 155.26
2nd Resistance Point 154.01
1st Resistance Point 153.33
Last Price 152.65
1st Support Level 151.40
2nd Support Level 150.15
3rd Support Level 149.47

See More

52-Week High 186.69
Fibonacci 61.8% 172.72
Fibonacci 50% 168.40
Fibonacci 38.2% 164.08
Last Price 152.65
52-Week Low 150.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar